This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rite Aid Is in Full Recovery Mode

NEW YORK (TheStreet) -- Rite Aid (RAD - Get Report) shares have surged after reporting fantastic results for the last quarter.

The company left the intensive care unit from 2012 when the shares traded for about a buck and shareholders wondered if the pharmacy would make it through to the other side. Rite Aid is now a prescription for continued profits, its shares at a healthy $7, up 39% for the year to date.

RAD Chart

Adding fuel to an already impressive increase in price is a 50% income beat of 6 cents per diluted share for a total of $55.4 million on revenue of $6.6 billion. That compares to analysts' predicted 4 cents for the fourth quarter ending March 1.

For the full fiscal year, the company earned 23 cents per diluted share ($249.4 million) from $25.5 billion of revenue.

The question now weighing on shareholders is whether to take the money and run or hold out for more. It's a legitimate concern considering the 10% opening morning gap on Thursday. At the time of writing, shares are trading slightly below the $7.18 open, a bearish indication after a move higher of this magnitude.

Not surprising, given the over 600% rise in share price during the previous 16 months. TheStreet's Jonathan Heller believes you shouldn't get too bullish, and he is probably right about the easy money already being made. But that doesn't mean an oversized return isn't still on the table.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RAD $8.04 -0.06%
AAPL $93.66 -0.09%
FB $118.57 0.84%
GOOG $698.30 0.76%
TSLA $241.82 0.44%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs